Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Carbetocin is an oxytocin agonist used for prevention of postpartum bleeding after cesarean
delivery. First studies revealed in 2012 an analgesic effect of carbetocin, compared to its
parent substance oxytocin. This study will enroll 78 women undergoing cesarean delivery. In a
double-blind, prospective design patients will be either attributed to the oxytocin or the
carbetocin study arm. The primary endpoint will be the area of hyperalgesia around the
cesarean delivery scar. This will be performed with a von Frey hair, resulting in a
unpleasant feeling in the area of hyperalgesia.